Adaptimmune Therapeutics plc (ADAP)
NASDAQ$0.4481
Market Cap
$19.11M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
421 of 925
Rank in Industry
246 of 528
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ADAP Insider Trading Activity
ADAP Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $128,064 | 14 | 100 |
Related Transactions
| Bertrand William C JR | Chief Operating Officer | 0 | $0 | 3 | $14,604 | $-14,604 |
| Lunger John | Chief Patient Supply Officer | 0 | $0 | 3 | $14,604 | $-14,604 |
| Norry Elliot | Chief Medical Officer | 0 | $0 | 3 | $16,163 | $-16,163 |
| Piccina Cintia | Chief Commercial Officer | 0 | $0 | 2 | $30,281 | $-30,281 |
| Rawcliffe Adrian | Chief Executive Officer | 0 | $0 | 3 | $52,413 | $-52,413 |
About Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and …
Insider Activity of Adaptimmune Therapeutics plc
Over the last 12 months, insiders at Adaptimmune Therapeutics plc have bought $0 and sold $128,064 worth of Adaptimmune Therapeutics plc stock.
On average, over the past 5 years, insiders at Adaptimmune Therapeutics plc have bought $86,498 and sold $1.51M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 39,000 shares for transaction amount of $11,326 was made by Wood Gavin (Chief Financial Officer) on 2022‑05‑20.
List of Insider Buy and Sell Transactions, Adaptimmune Therapeutics plc
| 2025-01-17 | Sale | Rawcliffe Adrian | Chief Executive Officer | 30,601 0.0121% | $0.58 | $17,773 | -1.26% | |
| 2025-01-17 | Sale | Norry Elliot | Chief Medical Officer | 5,584 0.0022% | $0.58 | $3,243 | -1.26% | |
| 2025-01-17 | Sale | Lunger John | Chief Patient Supply Officer | 5,584 0.0022% | $0.58 | $3,243 | -1.26% | |
| 2025-01-17 | Sale | Bertrand William C JR | Chief Operating Officer | 5,584 0.0022% | $0.58 | $3,243 | -1.26% | |
| 2025-01-15 | Sale | Rawcliffe Adrian | Chief Executive Officer | 29,096 0.0107% | $0.57 | $16,724 | -5.57% | |
| 2025-01-15 | Sale | Piccina Cintia | Chief Commercial Officer | 12,991 0.0048% | $0.57 | $7,467 | -5.57% | |
| 2025-01-15 | Sale | Norry Elliot | Chief Medical Officer | 9,803 0.0036% | $0.57 | $5,635 | -5.57% | |
| 2025-01-15 | Sale | Lunger John | Chief Patient Supply Officer | 9,803 0.0036% | $0.57 | $5,635 | -5.57% | |
| 2025-01-15 | Sale | Bertrand William C JR | Chief Operating Officer | 9,803 0.0036% | $0.57 | $5,635 | -5.57% | |
| 2025-01-13 | Sale | Rawcliffe Adrian | Chief Executive Officer | 30,473 0.0118% | $0.59 | $17,915 | -3.66% | |
| 2025-01-13 | Sale | Norry Elliot | Chief Medical Officer | 12,392 0.0048% | $0.59 | $7,285 | -3.66% | |
| 2025-01-13 | Sale | Lunger John | Chief Patient Supply Officer | 9,739 0.0038% | $0.59 | $5,726 | -3.66% | |
| 2025-01-13 | Sale | Bertrand William C JR | Chief Operating Officer | 9,739 0.0038% | $0.59 | $5,726 | -3.66% | |
| 2024-06-18 | Sale | Piccina Cintia | Chief Commercial Officer | 24,531 0.0086% | $0.93 | $22,814 | -9.11% | |
| 2024-01-17 | Sale | Rawcliffe Adrian | Chief Executive Officer | 30,080 0.0124% | $0.67 | $20,244 | +43.43% | |
| 2024-01-17 | Sale | Norry Elliot | Chief Medical Officer | 18,276 0.0075% | $0.67 | $12,300 | +43.43% | |
| 2024-01-17 | Sale | Lunger John | Chief Patient Supply Officer | 18,114 0.0075% | $0.67 | $12,191 | +43.43% | |
| 2024-01-17 | Sale | Bertrand William C JR | Chief Operating Officer | 18,908 0.0078% | $0.67 | $12,725 | +43.43% | |
| 2024-01-16 | Sale | Rawcliffe Adrian | Chief Executive Officer | 9,304 0.0046% | $0.79 | $7,350 | +46.48% | |
| 2024-01-16 | Sale | Lunger John | Chief Patient Supply Officer | 4,681 0.0023% | $0.79 | $3,698 | +46.48% |
Total: 220
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Bertrand William C JR | Chief Operating Officer | 7510 0.0176% | $3,365.23 | 1 | 21 | +23.78% |
| BARRIS PETER J | 10 percent owner | 82978668 194.5702% | $37.18M | 7 | 0 | <0.0001% |
| BARRETT M JAMES | 10 percent owner | 82978668 194.5702% | $37.18M | 7 | 0 | <0.0001% |
| KERINS PATRICK J | 10 percent owner | 82978668 194.5702% | $37.18M | 7 | 0 | <0.0001% |
| Viswanathan Ravi | 10 percent owner | 82978668 194.5702% | $37.18M | 7 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
Adaptimmune Therapeutics plc (ADAP) | $992,222,850 | 90 | -12.52% | $19.11M |
$6,204,522 | 45 | 1.91% | $18.93M | |
$550,024 | 37 | -2.68% | $19.79M | |
$85,897,100 | 36 | 2.47% | $16.75M | |
$217,684 | 34 | 1.61% | $17.84M |
ADAP Institutional Investors: Active Positions
| Increased Positions | 31 | +30.1% | 24M | +16.12% |
| Decreased Positions | 38 | -36.89% | 52M | -34.17% |
| New Positions | 13 | New | 16M | New |
| Sold Out Positions | 17 | Sold Out | 38M | Sold Out |
| Total Postitions | 96 | -6.8% | 124M | -18.05% |
ADAP Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Ecor1 Capital, Llc | $14,798.00 | 1.79% | 27.4M | 0 | 0% | 2024-12-31 |
| Long Focus Capital Management, Llc | $11,067.00 | 1.34% | 20.49M | +7M | +54.09% | 2024-12-31 |
| Nea Management Company, Llc | $9,223.00 | 1.11% | 17.08M | 0 | 0% | 2024-12-31 |
| Two Seas Capital Lp | $8,011.00 | 0.97% | 14.84M | +15M | New | 2024-12-31 |
| Baillie Gifford & Co | $6,382.00 | 0.77% | 11.82M | -5M | -29.55% | 2024-12-31 |
| Mpm Asset Management Llc | $3,000.00 | 0.36% | 5.56M | 0 | 0% | 2024-12-31 |
| Mpm Bioimpact Llc | $2,752.00 | 0.33% | 5.1M | 0 | 0% | 2024-12-31 |
| Pfm Health Sciences, Lp | $2,631.00 | 0.32% | 4.87M | -5M | -51.28% | 2024-12-31 |
| Bank Of America Corp /De/ | $1,546.00 | 0.19% | 2.86M | -2M | -38.49% | 2024-12-31 |
| Renaissance Technologies Llc | $1,364.00 | 0.17% | 2.53M | +869,949 | +52.52% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.